Stock Scorecard
Stock Summary for Theravance Biopharma Inc (TBPH) - $9.97 as of 11/20/2024 8:46:02 PM EST
Total Score
10 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TBPH
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TBPH
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TBPH
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TBPH
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for TBPH (25 out of 90)
Stock Price Rating (Max of 10) | 4 |
Historical Stock Price Rating (Max of 10) | 6 |
Stock Price Trend (Max of 10) | 2 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 2 |
Analyst Strong Buy Ratings (Max of 5) | 3 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 5 |
Price to Earnings (Max of 10) | 0 |
Latest News for for TBPH
Financial Details for TBPH
Company Overview |
|
---|---|
Ticker | TBPH |
Company Name | Theravance Biopharma Inc |
Country | USA |
Description | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 9.97 |
Price 4 Years Ago | 17.77 |
Last Day Price Updated | 11/20/2024 8:46:02 PM EST |
Last Day Volume | 352,847 |
Average Daily Volume | 166,848 |
52-Week High | 11.71 |
52-Week Low | 7.44 |
Last Price to 52 Week Low | 34.01% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | -9.99 |
Free Cash Flow Ratio | 5.36 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 4.97 |
Total Cash Per Share | 1.86 |
Book Value Per Share Most Recent Quarter | 3.79 |
Price to Book Ratio | 2.52 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 7.41 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 1 |
Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
Total Shares Outstanding | 49,174,300 |
Market Capitalization | 490,267,771 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -106.33% |
Reported EPS 12 Trailing Months | -1.03 |
Reported EPS Past Year | -0.58 |
Reported EPS Prior Year | -0.97 |
Net Income Twelve Trailing Months | -49,401,000 |
Net Income Past Year | -55,193,000 |
Net Income Prior Year | 872,132,000 |
Quarterly Revenue Growth YOY | 7.50% |
5-Year Revenue Growth | -0.79% |
Operating Margin Twelve Trailing Months | -0.55 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 91,361,000 |
Total Cash Past Year | 102,426,000 |
Total Cash Prior Year | 327,484,000 |
Net Cash Position Most Recent Quarter | 91,361,000 |
Net Cash Position Past Year | 102,426,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 616,334,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 212,995,000 |
Total Stockholder Equity Prior Year | 441,800,000 |
Total Stockholder Equity Most Recent Quarter | 185,654,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -12,306,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.25 |
Free Cash Flow Past Year | -29,485,000 |
Free Cash Flow Prior Year | -187,563,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.24 |
MACD Signal | 0.13 |
20-Day Bollinger Lower Band | 7.25 |
20-Day Bollinger Middle Band | 8.63 |
20-Day Bollinger Upper Band | 10.01 |
Beta | 0.25 |
RSI | 75.62 |
50-Day SMA | 9.08 |
150-Day SMA | 9.69 |
200-Day SMA | 10.85 |
System |
|
Modified | 11/19/2024 1:59:53 PM EST |